Clinical Study

Lp-168-Us-I01 A Phase I, Multicenter, Open-Label, Dose-Escalation Study To Evaluate Safety, Tolerability, Pharmacokinetics, And Clinical Activity Of Orally Administered Lp-168 In Subjects With Relapsed Or Refractory B-Cell Malignancies

Posted Date: Aug 24, 2021

  • Investigator: John Byrd
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor. This study will consist of two experimental arms. Efficacy will be determined by the maximum tolerated dose, recommended phase 2 dose, and the pharmacokinetic profile of Lp-168.


Subjects Are Eligible With B-Cell Malignancies, Wm, Fl, Mcl, Mzl, Dlbcl, Hcl, Cll, Sll, Based Upon 2016 Updated Who Classification. Those Subjects With Wm, Fl, Mcl, Dlbcl, Or Hcl Must Have Received At Least 2 Prior Systemic Therapies. Low-Grade B-Cell Lymphomas As Follicular Grade 1, 2, Or 3A, Marginal Zone Or Small Lymphocytic Lymphoma. Activated Partial Thromboplastin Time (Aptt) And Prothrombin Time (Pt) Not To Exceed 1.5 × Uln. Calculated Creatinine Clearance (Crcl) = 60 Ml/Min Using 24-Hour Crcl Or Cockcroft-Gault Formula. Aspartate Aminotransferase (Ast) And Alanine Aminotransferase (Alt) = 1.5 ×Uln; Bilirubin = 1.5 × Uln. Absolute Neutrophil Count (Anc) =1000/Ul. Platelet Count = 50,000/Μl - Or - Platelet Count = 20,000/ Μl If Thrombocytopenia Is Clearly Due To Cll Disease Under Study. No Subjects Who Require Immediate Cytoreduction. No Serum Amylase > 1.5 × Uln Or Serum Lipase > 1.5 × Uln. No Subject That Has Any History Of Richter's Transformation For Phase 1A Portion Of The Trial.


Malignancy, Phase 1

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.